Loading…

cDNA microarray study to identify expression changes relevant for apoptosis in K562 cells co-treated with amifostine and imatinib

Chronic myeloid leukemia is a clonal myeloproliferative disorder characterized by the presence of the fusion gene BCR/ABL. We had previously demonstrated an increased proapoptotic effect of imatinib (STI571) in combination with amifostine (AMI) in K562 cell line. In this study, we used genomic scale...

Full description

Saved in:
Bibliographic Details
Published in:Cancer chemotherapy and pharmacology 2007-03, Vol.59 (3), p.349-360
Main Authors: BIANCHINI, Michele, MARTINELLI, Giovanni, RENZULLI, Matteo, GONZALEZ CID, Marcela, LARRIPA, Irene
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c387t-ef9e441a0f942de406dc7f88d4d76d8f6dcfe5ea2c9df0b0ae74c0878bee06bb3
cites cdi_FETCH-LOGICAL-c387t-ef9e441a0f942de406dc7f88d4d76d8f6dcfe5ea2c9df0b0ae74c0878bee06bb3
container_end_page 360
container_issue 3
container_start_page 349
container_title Cancer chemotherapy and pharmacology
container_volume 59
creator BIANCHINI, Michele
MARTINELLI, Giovanni
RENZULLI, Matteo
GONZALEZ CID, Marcela
LARRIPA, Irene
description Chronic myeloid leukemia is a clonal myeloproliferative disorder characterized by the presence of the fusion gene BCR/ABL. We had previously demonstrated an increased proapoptotic effect of imatinib (STI571) in combination with amifostine (AMI) in K562 cell line. In this study, we used genomic scale gene expression profiling to monitor changes at transcriptional level in K562 cells during the treatment with AMI + STI571. cRNA from Control and treated K562 cells were mixed in equal amounts and incubated with a microarray slide for hybridization. RNA from six independent paired experiments was subjected to transcriptional profiling. With the aim to automate the process of biological theme determination, selected genes were further analyzed by EASE. Validation of the expression was carried out by quantitative real-time PCR and western blotting. As expected, a small percentage of genes accounts for the effects of the combined drug treatment. We identified 61 sequences corresponding to known genes; 17 of the 61 genes were up regulated, such as RHO6, PPP2R5E, PPM1E and BTF that appear to reflect favorable events for apoptosis induction. Between down regulated genes, API5, TUBB2 and TLK1 are also of considerable interest. We identified a transcriptional repressor of survival genes, known as BTF, which triggers a proapoptotic signal, potentially helpful to overcome the resistance to STI571. This finding could be particularly useful to design novel therapeutic strategies for leukemia patients. This study demonstrates the importance of in vitro testing of a novel drug combination most likely to predict its potential usefulness for in vivo application.
doi_str_mv 10.1007/s00280-006-0276-8
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_68378448</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>21212880</sourcerecordid><originalsourceid>FETCH-LOGICAL-c387t-ef9e441a0f942de406dc7f88d4d76d8f6dcfe5ea2c9df0b0ae74c0878bee06bb3</originalsourceid><addsrcrecordid>eNqFkU2P1SAUhonROHdGf4AbQ0ycXfVQaKHLyfgZJ7rRdUPh4DDphQpUvUv_uTT3JpO4MSyA5DlveHkIecbgFQOQrzNAq6AB6BtoZd-oB2THBG8bUII_JDvgQjSdBHFGznO-AwDBOH9MzpgEGIDLHflj3ny-ontvUtQp6QPNZbUHWiL1FkPx7kDx95IwZx8DNbc6fMdME874U4dCXUxUL3EpMftMfaCfur6lBuc5UxObklAXtPSXL7dU772LufiAVAdL_V7Xs5-ekEdOzxmfnvYL8u3d26_XH5qbL-8_Xl_dNIYrWRp0AwrBNLhBtBYF9NZIp5QVVvZWuXp12KFuzWAdTKBRCgNKqgkR-mniF-TymLuk-GPFXMa9z9tLdcC45rFXXCoh1H_BltWlFFTwxT_gXVxTqCUqwzsuermlsSNUfzjnhG5cUq2eDiODcbM4Hi2O1eK4WRy3meen4HXao72fOGmrwMsToLPRs0s6GJ_vudoDuoHxv5VQptU</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>213534678</pqid></control><display><type>article</type><title>cDNA microarray study to identify expression changes relevant for apoptosis in K562 cells co-treated with amifostine and imatinib</title><source>Springer Nature</source><creator>BIANCHINI, Michele ; MARTINELLI, Giovanni ; RENZULLI, Matteo ; GONZALEZ CID, Marcela ; LARRIPA, Irene</creator><creatorcontrib>BIANCHINI, Michele ; MARTINELLI, Giovanni ; RENZULLI, Matteo ; GONZALEZ CID, Marcela ; LARRIPA, Irene</creatorcontrib><description>Chronic myeloid leukemia is a clonal myeloproliferative disorder characterized by the presence of the fusion gene BCR/ABL. We had previously demonstrated an increased proapoptotic effect of imatinib (STI571) in combination with amifostine (AMI) in K562 cell line. In this study, we used genomic scale gene expression profiling to monitor changes at transcriptional level in K562 cells during the treatment with AMI + STI571. cRNA from Control and treated K562 cells were mixed in equal amounts and incubated with a microarray slide for hybridization. RNA from six independent paired experiments was subjected to transcriptional profiling. With the aim to automate the process of biological theme determination, selected genes were further analyzed by EASE. Validation of the expression was carried out by quantitative real-time PCR and western blotting. As expected, a small percentage of genes accounts for the effects of the combined drug treatment. We identified 61 sequences corresponding to known genes; 17 of the 61 genes were up regulated, such as RHO6, PPP2R5E, PPM1E and BTF that appear to reflect favorable events for apoptosis induction. Between down regulated genes, API5, TUBB2 and TLK1 are also of considerable interest. We identified a transcriptional repressor of survival genes, known as BTF, which triggers a proapoptotic signal, potentially helpful to overcome the resistance to STI571. This finding could be particularly useful to design novel therapeutic strategies for leukemia patients. This study demonstrates the importance of in vitro testing of a novel drug combination most likely to predict its potential usefulness for in vivo application.</description><identifier>ISSN: 0344-5704</identifier><identifier>EISSN: 1432-0843</identifier><identifier>DOI: 10.1007/s00280-006-0276-8</identifier><identifier>PMID: 17009037</identifier><identifier>CODEN: CCPHDZ</identifier><language>eng</language><publisher>Berlin: Springer</publisher><subject>Amifostine - administration &amp; dosage ; Antineoplastic agents ; Antineoplastic Combined Chemotherapy Protocols - pharmacology ; Apoptosis - drug effects ; Benzamides ; Biological and medical sciences ; Cell Survival - drug effects ; DNA-Binding Proteins - genetics ; Drug Combinations ; Drug Screening Assays, Antitumor ; Gene Expression Profiling ; Gene Expression Regulation, Neoplastic - physiology ; Humans ; Imatinib Mesylate ; K562 Cells - drug effects ; K562 Cells - pathology ; Medical sciences ; Oligonucleotide Array Sequence Analysis - methods ; Pharmacology. Drug treatments ; Piperazines - administration &amp; dosage ; Pyrimidines - administration &amp; dosage ; Repressor Proteins - genetics ; Reverse Transcriptase Polymerase Chain Reaction ; Transcription Factors - genetics ; Transcription, Genetic - drug effects ; Tumor Suppressor Proteins - genetics</subject><ispartof>Cancer chemotherapy and pharmacology, 2007-03, Vol.59 (3), p.349-360</ispartof><rights>2007 INIST-CNRS</rights><rights>Springer-Verlag 2007</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c387t-ef9e441a0f942de406dc7f88d4d76d8f6dcfe5ea2c9df0b0ae74c0878bee06bb3</citedby><cites>FETCH-LOGICAL-c387t-ef9e441a0f942de406dc7f88d4d76d8f6dcfe5ea2c9df0b0ae74c0878bee06bb3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=18440591$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/17009037$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>BIANCHINI, Michele</creatorcontrib><creatorcontrib>MARTINELLI, Giovanni</creatorcontrib><creatorcontrib>RENZULLI, Matteo</creatorcontrib><creatorcontrib>GONZALEZ CID, Marcela</creatorcontrib><creatorcontrib>LARRIPA, Irene</creatorcontrib><title>cDNA microarray study to identify expression changes relevant for apoptosis in K562 cells co-treated with amifostine and imatinib</title><title>Cancer chemotherapy and pharmacology</title><addtitle>Cancer Chemother Pharmacol</addtitle><description>Chronic myeloid leukemia is a clonal myeloproliferative disorder characterized by the presence of the fusion gene BCR/ABL. We had previously demonstrated an increased proapoptotic effect of imatinib (STI571) in combination with amifostine (AMI) in K562 cell line. In this study, we used genomic scale gene expression profiling to monitor changes at transcriptional level in K562 cells during the treatment with AMI + STI571. cRNA from Control and treated K562 cells were mixed in equal amounts and incubated with a microarray slide for hybridization. RNA from six independent paired experiments was subjected to transcriptional profiling. With the aim to automate the process of biological theme determination, selected genes were further analyzed by EASE. Validation of the expression was carried out by quantitative real-time PCR and western blotting. As expected, a small percentage of genes accounts for the effects of the combined drug treatment. We identified 61 sequences corresponding to known genes; 17 of the 61 genes were up regulated, such as RHO6, PPP2R5E, PPM1E and BTF that appear to reflect favorable events for apoptosis induction. Between down regulated genes, API5, TUBB2 and TLK1 are also of considerable interest. We identified a transcriptional repressor of survival genes, known as BTF, which triggers a proapoptotic signal, potentially helpful to overcome the resistance to STI571. This finding could be particularly useful to design novel therapeutic strategies for leukemia patients. This study demonstrates the importance of in vitro testing of a novel drug combination most likely to predict its potential usefulness for in vivo application.</description><subject>Amifostine - administration &amp; dosage</subject><subject>Antineoplastic agents</subject><subject>Antineoplastic Combined Chemotherapy Protocols - pharmacology</subject><subject>Apoptosis - drug effects</subject><subject>Benzamides</subject><subject>Biological and medical sciences</subject><subject>Cell Survival - drug effects</subject><subject>DNA-Binding Proteins - genetics</subject><subject>Drug Combinations</subject><subject>Drug Screening Assays, Antitumor</subject><subject>Gene Expression Profiling</subject><subject>Gene Expression Regulation, Neoplastic - physiology</subject><subject>Humans</subject><subject>Imatinib Mesylate</subject><subject>K562 Cells - drug effects</subject><subject>K562 Cells - pathology</subject><subject>Medical sciences</subject><subject>Oligonucleotide Array Sequence Analysis - methods</subject><subject>Pharmacology. Drug treatments</subject><subject>Piperazines - administration &amp; dosage</subject><subject>Pyrimidines - administration &amp; dosage</subject><subject>Repressor Proteins - genetics</subject><subject>Reverse Transcriptase Polymerase Chain Reaction</subject><subject>Transcription Factors - genetics</subject><subject>Transcription, Genetic - drug effects</subject><subject>Tumor Suppressor Proteins - genetics</subject><issn>0344-5704</issn><issn>1432-0843</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2007</creationdate><recordtype>article</recordtype><recordid>eNqFkU2P1SAUhonROHdGf4AbQ0ycXfVQaKHLyfgZJ7rRdUPh4DDphQpUvUv_uTT3JpO4MSyA5DlveHkIecbgFQOQrzNAq6AB6BtoZd-oB2THBG8bUII_JDvgQjSdBHFGznO-AwDBOH9MzpgEGIDLHflj3ny-ontvUtQp6QPNZbUHWiL1FkPx7kDx95IwZx8DNbc6fMdME874U4dCXUxUL3EpMftMfaCfur6lBuc5UxObklAXtPSXL7dU772LufiAVAdL_V7Xs5-ekEdOzxmfnvYL8u3d26_XH5qbL-8_Xl_dNIYrWRp0AwrBNLhBtBYF9NZIp5QVVvZWuXp12KFuzWAdTKBRCgNKqgkR-mniF-TymLuk-GPFXMa9z9tLdcC45rFXXCoh1H_BltWlFFTwxT_gXVxTqCUqwzsuermlsSNUfzjnhG5cUq2eDiODcbM4Hi2O1eK4WRy3meen4HXao72fOGmrwMsToLPRs0s6GJ_vudoDuoHxv5VQptU</recordid><startdate>20070301</startdate><enddate>20070301</enddate><creator>BIANCHINI, Michele</creator><creator>MARTINELLI, Giovanni</creator><creator>RENZULLI, Matteo</creator><creator>GONZALEZ CID, Marcela</creator><creator>LARRIPA, Irene</creator><general>Springer</general><general>Springer Nature B.V</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7TO</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>H94</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7QO</scope><scope>7TM</scope><scope>8FD</scope><scope>FR3</scope><scope>P64</scope><scope>7X8</scope></search><sort><creationdate>20070301</creationdate><title>cDNA microarray study to identify expression changes relevant for apoptosis in K562 cells co-treated with amifostine and imatinib</title><author>BIANCHINI, Michele ; MARTINELLI, Giovanni ; RENZULLI, Matteo ; GONZALEZ CID, Marcela ; LARRIPA, Irene</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c387t-ef9e441a0f942de406dc7f88d4d76d8f6dcfe5ea2c9df0b0ae74c0878bee06bb3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2007</creationdate><topic>Amifostine - administration &amp; dosage</topic><topic>Antineoplastic agents</topic><topic>Antineoplastic Combined Chemotherapy Protocols - pharmacology</topic><topic>Apoptosis - drug effects</topic><topic>Benzamides</topic><topic>Biological and medical sciences</topic><topic>Cell Survival - drug effects</topic><topic>DNA-Binding Proteins - genetics</topic><topic>Drug Combinations</topic><topic>Drug Screening Assays, Antitumor</topic><topic>Gene Expression Profiling</topic><topic>Gene Expression Regulation, Neoplastic - physiology</topic><topic>Humans</topic><topic>Imatinib Mesylate</topic><topic>K562 Cells - drug effects</topic><topic>K562 Cells - pathology</topic><topic>Medical sciences</topic><topic>Oligonucleotide Array Sequence Analysis - methods</topic><topic>Pharmacology. Drug treatments</topic><topic>Piperazines - administration &amp; dosage</topic><topic>Pyrimidines - administration &amp; dosage</topic><topic>Repressor Proteins - genetics</topic><topic>Reverse Transcriptase Polymerase Chain Reaction</topic><topic>Transcription Factors - genetics</topic><topic>Transcription, Genetic - drug effects</topic><topic>Tumor Suppressor Proteins - genetics</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>BIANCHINI, Michele</creatorcontrib><creatorcontrib>MARTINELLI, Giovanni</creatorcontrib><creatorcontrib>RENZULLI, Matteo</creatorcontrib><creatorcontrib>GONZALEZ CID, Marcela</creatorcontrib><creatorcontrib>LARRIPA, Irene</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database (Proquest)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>PML(ProQuest Medical Library)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>Biotechnology Research Abstracts</collection><collection>Nucleic Acids Abstracts</collection><collection>Technology Research Database</collection><collection>Engineering Research Database</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Cancer chemotherapy and pharmacology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>BIANCHINI, Michele</au><au>MARTINELLI, Giovanni</au><au>RENZULLI, Matteo</au><au>GONZALEZ CID, Marcela</au><au>LARRIPA, Irene</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>cDNA microarray study to identify expression changes relevant for apoptosis in K562 cells co-treated with amifostine and imatinib</atitle><jtitle>Cancer chemotherapy and pharmacology</jtitle><addtitle>Cancer Chemother Pharmacol</addtitle><date>2007-03-01</date><risdate>2007</risdate><volume>59</volume><issue>3</issue><spage>349</spage><epage>360</epage><pages>349-360</pages><issn>0344-5704</issn><eissn>1432-0843</eissn><coden>CCPHDZ</coden><abstract>Chronic myeloid leukemia is a clonal myeloproliferative disorder characterized by the presence of the fusion gene BCR/ABL. We had previously demonstrated an increased proapoptotic effect of imatinib (STI571) in combination with amifostine (AMI) in K562 cell line. In this study, we used genomic scale gene expression profiling to monitor changes at transcriptional level in K562 cells during the treatment with AMI + STI571. cRNA from Control and treated K562 cells were mixed in equal amounts and incubated with a microarray slide for hybridization. RNA from six independent paired experiments was subjected to transcriptional profiling. With the aim to automate the process of biological theme determination, selected genes were further analyzed by EASE. Validation of the expression was carried out by quantitative real-time PCR and western blotting. As expected, a small percentage of genes accounts for the effects of the combined drug treatment. We identified 61 sequences corresponding to known genes; 17 of the 61 genes were up regulated, such as RHO6, PPP2R5E, PPM1E and BTF that appear to reflect favorable events for apoptosis induction. Between down regulated genes, API5, TUBB2 and TLK1 are also of considerable interest. We identified a transcriptional repressor of survival genes, known as BTF, which triggers a proapoptotic signal, potentially helpful to overcome the resistance to STI571. This finding could be particularly useful to design novel therapeutic strategies for leukemia patients. This study demonstrates the importance of in vitro testing of a novel drug combination most likely to predict its potential usefulness for in vivo application.</abstract><cop>Berlin</cop><pub>Springer</pub><pmid>17009037</pmid><doi>10.1007/s00280-006-0276-8</doi><tpages>12</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0344-5704
ispartof Cancer chemotherapy and pharmacology, 2007-03, Vol.59 (3), p.349-360
issn 0344-5704
1432-0843
language eng
recordid cdi_proquest_miscellaneous_68378448
source Springer Nature
subjects Amifostine - administration & dosage
Antineoplastic agents
Antineoplastic Combined Chemotherapy Protocols - pharmacology
Apoptosis - drug effects
Benzamides
Biological and medical sciences
Cell Survival - drug effects
DNA-Binding Proteins - genetics
Drug Combinations
Drug Screening Assays, Antitumor
Gene Expression Profiling
Gene Expression Regulation, Neoplastic - physiology
Humans
Imatinib Mesylate
K562 Cells - drug effects
K562 Cells - pathology
Medical sciences
Oligonucleotide Array Sequence Analysis - methods
Pharmacology. Drug treatments
Piperazines - administration & dosage
Pyrimidines - administration & dosage
Repressor Proteins - genetics
Reverse Transcriptase Polymerase Chain Reaction
Transcription Factors - genetics
Transcription, Genetic - drug effects
Tumor Suppressor Proteins - genetics
title cDNA microarray study to identify expression changes relevant for apoptosis in K562 cells co-treated with amifostine and imatinib
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-24T17%3A38%3A10IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=cDNA%20microarray%20study%20to%20identify%20expression%20changes%20relevant%20for%20apoptosis%20in%20K562%20cells%20co-treated%20with%20amifostine%20and%20imatinib&rft.jtitle=Cancer%20chemotherapy%20and%20pharmacology&rft.au=BIANCHINI,%20Michele&rft.date=2007-03-01&rft.volume=59&rft.issue=3&rft.spage=349&rft.epage=360&rft.pages=349-360&rft.issn=0344-5704&rft.eissn=1432-0843&rft.coden=CCPHDZ&rft_id=info:doi/10.1007/s00280-006-0276-8&rft_dat=%3Cproquest_cross%3E21212880%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c387t-ef9e441a0f942de406dc7f88d4d76d8f6dcfe5ea2c9df0b0ae74c0878bee06bb3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=213534678&rft_id=info:pmid/17009037&rfr_iscdi=true